Ravindra Majeti

Publications

• Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia. Jan M, Snyder TM, Corces-Zimmerman MR, Vyas P, Weissman IL, Quake SR, Majeti R. Sci Transl Med. 2012; 4 (149): 149ra118
• Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Jan M, Chao MP, Cha AC, Alizadeh AA, Gentles AJ, Weissman IL, Majeti R. Proc Natl Acad Sci U S A. 2011; 108 (12): 5009-14
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Cell. 2010; 142 (5): 699-713
• Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. JAMA. 2010; 304 (24): 2706-15
• CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. Cell. 2009; 138 (2): 286-99
• Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL. Proc Natl Acad Sci U S A. 2009; 106 (9): 3396-401
• Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Majeti R, Park CY, Weissman IL. Cell Stem Cell. 2007; 1 (6): 635-45
• Clonal evolution of acute leukemia genomes. Jan M, Majeti R. Oncogene. 2013; 32 (2): 135-40
• The cancer stem cell model: B cell acute lymphoblastic leukaemia breaks the mould. McClellan JS, Majeti R. EMBO Mol Med. 2013; 5 (1): 7-9
• Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, Beck AH, Weissman IL, van de Rijn M. Proc Natl Acad Sci U S A. 2012; 109 (17): 6656-61
• Programmed cell removal: a new obstacle in the road to developing cancer. Chao MP, Majeti R, Weissman IL. Nat Rev Cancer. 2012; 12 (1): 58-67
• The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Chao MP, Weissman IL, Majeti R. Curr Opin Immunol. 2012; 24 (2): 225-32
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, Volkmer AK, Naik TJ, Storm TA, Mosley AR, Edris B, Schmid SM, Sun CK, Chua MS, Murillo O, Rajendran P, Cha AC, Chin RK, Kim D, Adorno M, Raveh T, Tseng D, Jaiswal S, Enger PØ, Steinberg GK, Li G, So SK, Majeti R, Harsh GR, van de Rijn M, Teng NN, Sunwoo JB, Alizadeh AA, Clarke MF, Weissman IL. Proc Natl Acad Sci U S A. 2012; 109 (17): 6662-7
• Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Blood. 2011; 118 (18): 4890-901
• Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Majeti R, Weissman IL. Cancer Cell. 2011; 19 (1): 9-10
• Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Majeti R, Oncogene. 2011; 30 (9): 1009-19
• Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Gibbs KD, Gilbert PM, Sachs K, Zhao F, Blau HM, Weissman IL, Nolan GP, Majeti R. Blood. 2011; 117 (16): 4226-33
• Surprise! HSC are aberrant in chronic lymphocytic leukemia. Alizadeh AA, Majeti R. Cancer Cell. 2011; 20 (2): 135-6
• Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL, Majeti R. Cancer Res. 2011; 71 (4): 1374-84
• Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J, Weiskopf K, Willingham SB, Raveh T, Park CY, Majeti R, Weissman IL. Sci Transl Med. 2010; 2 (63): 63ra94
• Immunophenotypic features of acute myeloid leukemia with inv(3)(q21q26.2)/t(3;3)(q21;q26.2). Medeiros BC, Kohrt HE, Arber DA, Bangs CD, Cherry AM, Majeti R, Kogel KE, Azar CA, Patel S, Alizadeh AA. Leuk Res. 2010; 34 (5): 594-7
• Macrophages as mediators of tumor immunosurveillance. Jaiswal S, Chao MP, Majeti R, Weissman IL. Trends Immunol. 2010; 31 (6): 212-9
• Metastatic cancer stem cells: an opportunity for improving cancer treatment? Diehn M, Majeti R. Cell Stem Cell. 2010; 6 (6): 502-3
• Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience. Kohrt HE, Patel S, Ho M, Owen T, Pollyea DA, Majeti R, Gotlib J, Coutre S, Liedtke M, Berube C, Alizadeh AA, Medeiros BC. Am J Hematol. 2010; 85 (11): 877-81
• CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N, Weissman IL. Cell. 2009; 138 (2): 271-85
• The adhesion molecule esam1 is a novel hematopoietic stem cell marker. Ooi AG, Karsunky H, Majeti R, Butz S, Vestweber D, Ishida T, Quertermous T, Weissman IL, Forsberg EC. Stem Cells. 2009; 27 (3): 653-61
• In vivo evaluation of human hematopoiesis through xenotransplantation of purified hematopoietic stem cells from umbilical cord blood. Park CY, Majeti R, Weissman IL. Nat Protoc. 2008; 3 (12): 1932-40